Filing Flows › Comparisons › PRTA vs MIST
Prothena Corp Public vs Milestone Pharmaceuticals: PRTA and MIST compared
Prothena Corp Public is the larger company: $620K of revenue in its latest quarter (Q3 2026) against $559K for Milestone Pharmaceuticals (Q2 2026).
Where the money goes: PRTA and MIST
Prothena Corp Public (PRTA) · Q3 2026
Prothena Corp Public, Q3 2026: revenue $620K (-74% year over year), net loss $16.5M, operating cash flow −$12.0M. The chart follows the revenue to costs, profit and cash.
Milestone Pharmaceuticals (MIST) · Q2 2026
Milestone Pharmaceuticals, Q2 2026: revenue $559K, net loss $28.6M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
| Prothena Corp Public (PRTA) | Milestone Pharmaceuticals (MIST) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $620K | $559K |
| Revenue growth, Y/Y | -74% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$16.5M | −$28.6M |
| Operating cash flow | −$12.0M | −$22.7M |
Questions
Which is bigger, Prothena Corp Public or Milestone Pharmaceuticals?
Prothena Corp Public is the larger company: $620K of revenue in its latest quarter (Q3 2026) against $559K for Milestone Pharmaceuticals (Q2 2026).
More: Prothena Corp Public earnings · how Prothena Corp Public makes money · Milestone Pharmaceuticals earnings · how Milestone Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.